About Apolipoprotein A-IV
Apolipoprotein A-IV (APOA4) is a protein
from Homo sapiens identified by UniProt accession
P06727, 396 residues long.
MolForge cross-references it against 0 known binders and
338 disease associations.
Target properties
| Protein name | Apolipoprotein A-IV |
| UniProt accession | P06727 |
| Gene | APOA4 |
| Organism | Homo sapiens |
| Length | 396 residues |
| Molecular weight | — |
| EC numbers | — |
| Target class | UNCLASSIFIED |
| Subcellular location | — |
| Keywords | — |
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
| Druggability score | — |
| Pocket score | — |
| Max clinical phase | — |
Disease associations (338)
Diseases linked to this target (Open Targets).
- AL amyloidosis · score 0.46
- triglyceride measurement · score 0.42
- total cholesterol measurement · score 0.40
- high density lipoprotein cholesterol measurement · score 0.33
- low density lipoprotein cholesterol measurement · score 0.33
- apolipoprotein B measurement · score 0.24
- lung adenocarcinoma · score 0.24
- cutaneous melanoma · score 0.23
- apolipoprotein A-IV measurement · score 0.21
- apolipoprotein A 1 measurement · score 0.16
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
| AF-P06727-F1 | alphafold | PREDICTED | 80.81 | — |
Amino-acid sequence (396 residues)
MFLKAVVLTL ALVAVAGARA EVSADQVATV MWDYFSQLSN NAKEAVEHLQ KSELTQQLNA LFQDKLGEVN TYAGDLQKKL VPFATELHER LAKDSEKLKE EIGKELEELR ARLLPHANEV SQKIGDNLRE LQQRLEPYAD QLRTQVSTQA EQLRRQLTPY AQRMERVLRE NADSLQASLR PHADELKAKI DQNVEELKGR LTPYADEFKV KIDQTVEELR RSLAPYAQDT QEKLNHQLEG LTFQMKKNAE ELKARISASA EELRQRLAPL AEDVRGNLRG NTEGLQKSLA ELGGHLDQQV EEFRRRVEPY GENFNKALVQ QMEQLRQKLG PHAGDVEGHL SFLEKDLRDK VNSFFSTFKE KESQDKTLSL PELEQQQEQQ QEQQQEQVQM LAPLES
Explore Apolipoprotein A-IV with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets